Idade ≥75 com comorbidades ECOG ≥2 ou ≥2 — dose completa de lenvatinib (24 mg) mal tolerada;...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | RF-THYROID-PAPILLARY-FRAILTY-AGE |
|---|---|
| Tipo | Sinal de alerta |
| Estado | reviewed 2026-04-27 | pending_clinical_signoff |
| Doenças | DIS-THYROID-PAPILLARY |
| Fontes | SRC-ATA-THYROID-2015 SRC-NCCN-THYROID-2025 |
Origem da bandeira vermelha
| Definição | Age ≥75 with ECOG ≥2 or ≥2 comorbidities — lenvatinib full-dose (24 mg) poorly tolerated; consider lenvatinib 14 mg starting dose (Brose et al subgroup), selective RET / NTRK inhibitor monotherapy if fusion+, or watchful waiting if asymptomatic indolent metastatic disease (most PTC indolent — frail elderly often die with rather than from disease). |
|---|---|
| Direcção clínica | de escalonamento |
| Categoria | Idade de fragilidade |
Lógica de Desencadeamento
{
"all_of": [
{
"comparator": ">=",
"finding": "age_years",
"threshold": 75
},
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog_status",
"threshold": 2
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
}
],
"type": "composite_clinical"
}
Notas
PTC is the most indolent thyroid malignancy; for elderly with metastatic but asymptomatic disease, watchful waiting with serial thyroglobulin + imaging is appropriate (especially if doubling time >12 mo). Lenvatinib starting at 14 mg (vs 24 mg standard) tested in Study 211 — PFS comparable, lower hypertension / fatigue / proteinuria burden in elderly. Selpercatinib / pralsetinib (RET+) and larotrectinib / entrectinib (NTRK+) better tolerated than multikinase — preferred in frail elderly when biomarker-positive. Geriatric assessment (G8) ≥70 recommended before TKI initiation. Most PTC patients in this category will benefit more from symptom-focused care + low-dose TKI than full-dose induction.
Usado por
Não há referências reversas encontradas no corpus YAML.